Bath Savings Trust Co Purchases 3,521 Shares of Eli Lilly and Company $LLY

Bath Savings Trust Co boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,423 shares of the company’s stock after acquiring an additional 3,521 shares during the quarter. Eli Lilly and Company accounts for approximately 2.6% of Bath Savings Trust Co’s investment portfolio, making the stock its 9th biggest holding. Bath Savings Trust Co’s holdings in Eli Lilly and Company were worth $26,247,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after purchasing an additional 551,659 shares during the period. State Street Corp lifted its stake in Eli Lilly and Company by 0.6% in the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after purchasing an additional 219,590 shares during the last quarter. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Wellington Management Group LLP grew its holdings in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after purchasing an additional 574,229 shares during the period. Finally, Norges Bank acquired a new position in Eli Lilly and Company during the second quarter worth approximately $8,827,714,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 earnings and revenue momentum — Coverage highlights Eli Lilly’s strong Q4 results and robust GLP‑1 sales that are driving top‑line and margin strength, supporting the company’s growth story. Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
• Positive Sentiment: Bullish long‑term thesis on GLP‑1 leadership — Retail/bullish analysis argues that Lilly’s leadership in obesity/GLP‑1 drugs makes it a durable growth compounder, reinforcing investor enthusiasm. Could Buying Eli Lilly Today Set You Up for Life?
• Positive Sentiment: Analyst model tweak — Erste Group slightly raised FY‑2026 EPS expectations for LLY (minor lift to forecasts), which supports consensus that Lilly’s earnings power is rising. MarketBeat: Eli Lilly analyst note
• Neutral Sentiment: Media/celebrity endorsement and market performance — Jim Cramer and other outlets are naming Lilly among top healthcare picks, and recent trading showed short‑term outperformance, which can attract flows but also create volatility. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Industry comparisons and valuation debate — Analyst pieces compare LLY with peers (Novo Nordisk, ABBV), highlighting strong growth but also elevated multiples — important context for investors weighing upside vs. valuation risk. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Neutral Sentiment: Investor letters and fund commentary reiterate GLP‑1 as the growth engine, but also note concentration risk (revenue tied to a few franchises). Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Negative Sentiment: Policy/reputation risk around GLP‑1s — Coverage raising the “societal obligation” and broader public debate about GLP‑1s can translate into regulatory scrutiny or reimbursement pressure, a potential near‑term headwind for sentiment. Eli Lilly and the ‘societal obligation’ of GLP-1s

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $898.68 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a 50-day simple moving average of $1,010.46 and a two-hundred day simple moving average of $960.96. The stock has a market capitalization of $849.09 billion, a price-to-earnings ratio of 39.16, a price-to-earnings-growth ratio of 1.06 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the firm posted $5.32 EPS. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Scotiabank restated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Argus boosted their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, TD Cowen lifted their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.